AU2022415426A1 - Fused pyrrolidine psychoplastogens and uses thereof - Google Patents

Fused pyrrolidine psychoplastogens and uses thereof Download PDF

Info

Publication number
AU2022415426A1
AU2022415426A1 AU2022415426A AU2022415426A AU2022415426A1 AU 2022415426 A1 AU2022415426 A1 AU 2022415426A1 AU 2022415426 A AU2022415426 A AU 2022415426A AU 2022415426 A AU2022415426 A AU 2022415426A AU 2022415426 A1 AU2022415426 A1 AU 2022415426A1
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
alkyl
disorder
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022415426A
Other languages
English (en)
Inventor
Milan Chytil
Noel Aaron Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delix Therapeutics Inc
Original Assignee
Delix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delix Therapeutics Inc filed Critical Delix Therapeutics Inc
Publication of AU2022415426A1 publication Critical patent/AU2022415426A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14Ortho-condensed systems
    • C07D491/147Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022415426A 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof Pending AU2022415426A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290037P 2021-12-15 2021-12-15
US63/290,037 2021-12-15
US202263387225P 2022-12-13 2022-12-13
US63/387,225 2022-12-13
PCT/US2022/052879 WO2023114320A1 (en) 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof

Publications (1)

Publication Number Publication Date
AU2022415426A1 true AU2022415426A1 (en) 2024-07-25

Family

ID=86773439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022415426A Pending AU2022415426A1 (en) 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof

Country Status (9)

Country Link
EP (1) EP4448532A4 (https=)
JP (1) JP2025502614A (https=)
KR (1) KR20240150418A (https=)
AU (1) AU2022415426A1 (https=)
CA (1) CA3239571A1 (https=)
IL (1) IL313457A (https=)
MX (1) MX2024007220A (https=)
TW (1) TW202333736A (https=)
WO (1) WO2023114320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023025599A2 (pt) 2021-06-08 2024-02-20 Entheogenix Biosciences Inc Ativadores de dimetoxifenilalquilamina de receptores de serotonina.
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
EP4704822A1 (en) 2023-05-01 2026-03-11 ATAI Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO115522B1 (ro) * 1995-02-02 2000-03-30 Smithkline Beecham P.L.C. Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament
PE20010052A1 (es) * 1999-04-23 2001-01-27 Upjohn Co Compuestos de azepinindol tetraciclico como agonistas o antagonistas del receptor de 5-ht
AU2001292898A1 (en) * 2000-09-20 2002-04-02 Brad A. Acker Substituted azepino[4,5b)indole derivatives
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
US20230295106A1 (en) * 2019-10-14 2023-09-21 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity

Also Published As

Publication number Publication date
TW202333736A (zh) 2023-09-01
JP2025502614A (ja) 2025-01-28
IL313457A (en) 2024-08-01
EP4448532A4 (en) 2025-12-24
MX2024007220A (es) 2024-08-27
CA3239571A1 (en) 2023-06-22
KR20240150418A (ko) 2024-10-15
WO2023114320A1 (en) 2023-06-22
EP4448532A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
AU2022415426A1 (en) Fused pyrrolidine psychoplastogens and uses thereof
EP4165049A1 (en) Isotryptamine psychoplastogens and uses thereof
WO2021076572A1 (en) Ergoline-like compounds for promoting neural plasticity
EP4165042A1 (en) Tricyclic psychoplastogens and uses thereof
AU2022258453A1 (en) Tetracyclic compounds for treating brain disorders
US12295959B2 (en) Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023114238A1 (en) Aryloxy psychoplastogens and uses thereof
WO2023114858A1 (en) Benzofuran and benzothiophene psychoplastogens and uses thereof
WO2024258995A2 (en) Fused tetrahydroazepine psychoplastogens and uses thereof
WO2023114844A1 (en) Imidazopyridine psychoplastogens and uses thereof
WO2023114325A1 (en) Constrained amine psychoplastogens and uses thereof
WO2026072584A1 (en) Methods of using phenoxy and benzyloxy substituted neuroplastogens
WO2024258988A2 (en) Serotonin releasing compounds and uses thereof
CN118696047A (zh) 稠合吡咯烷精神重塑剂及其用途
CN118742551A (zh) 苯氧基和苄氧基取代的精神重塑剂及其用途
CN116507625A (zh) 异色胺神经可塑剂及其用途
WO2025137639A1 (en) Mixed serotonin receptor binders for treatment of psychotic disorders